The Score Right Now Is: Opioid Crisis 1, PixarBio 0

Forbes interviewed David Axelrod—a Partner in the firm’s Securities Enforcement and Corporate Governance Litigation and a former Supervisory Trial Counsel at the U.S. Securities and Exchange Commission's (SEC) Philadelphia Regional Office—for an article exploring enforcement actions against PixarBio, which has a non-opioid pain reliever in development.

Read the full article here. (Subscription may be required.)